Welcome to our dedicated page for Veeva Systems news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Systems stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) announced increasing momentum for Veeva Vault LIMS, a cloud solution that simplifies quality control (QC) processes. Vault LIMS is unified with Veeva Vault Quality, enabling customers to share data across quality applications for more informed batch release decisions. The solution aims to bring together quality assurance (QA) and QC to improve efficiency, compliance, and right-first-time execution.
Forge Biologics' senior director of QC analytical testing, Andrew Laughhunn, highlighted the potential for streamlined method execution and minimized documentation errors. Vault LIMS offers a complete QC management and test execution solution that can be deployed quickly, reducing reliance on IT teams and lowering total cost of ownership. The solution is suitable for both established organizations and fast-growing biotechs.
Veeva Systems (NYSE: VEEV) has announced the upcoming 2024 Veeva R&D and Quality Summit in Boston on Sept. 9-10. This event, one of the largest in life sciences, will bring together over 2,000 industry professionals to discuss how connected systems across clinical, regulatory, safety, and quality can advance drug development.
Keynote speakers from leading companies like AbbVie, Astellas, Eikon Therapeutics, Merck & Co., Moderna, and Roche will share insights on various topics. These include pharmacovigilance transformation, clinical process optimization, scalable development foundations, quality control modernization, and AI-powered translation for faster submissions.
Veeva CEO Peter Gassner will headline the opening keynote, focusing on how connected data and systems can streamline drug development and accelerate product time to market. The summit will feature over 100 sessions, providing ample networking and learning opportunities for attendees.
Veeva Systems (NYSE: VEEV) has announced that it will release its fiscal 2025 second quarter financial results on August 28, 2024, after the market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted to Veeva's investor relations website approximately at 1:05 p.m. PT (4:05 p.m. ET). Investors and analysts can register for the conference call, and a webcast replay will be available on the company's website following the live event.
Veeva Systems' latest Pulse Field Trends Report reveals that targeted pre-launch scientific outreach significantly accelerates treatment adoption. Key findings include:
1. Biopharmas investing in pre-launch scientific activities and prioritizing congresses achieve 40% faster treatment adoption.
2. Early-career experts are four times more likely to start patients on new treatments and more open to digital engagement.
3. Congress activity has the strongest influence on clinical decisions post-approval.
4. Engaging early-career HCPs increases new treatment uptake, with these experts being five times more likely to speak at congresses and 11 times more likely to engage digitally.
The report emphasizes the importance of expanding engagement strategies beyond traditional experts and investing in different types of scientific outreach to drive greater impact and faster treatment adoption.
Veeva Systems (NYSE: VEEV) announced a partnership with Vita Global Sciences to enhance clinical data management through Veeva Vault EDC. This collaboration aims to streamline processes, improve patient and stakeholder experiences, and accelerate study builds. Kelly Forester, director of clinical data management at Vita Global Sciences, highlighted the goal of delivering impactful innovations. Future plans include integrating Veeva Clinical Database (CDB) and Veeva RTSM to further optimize trial data management and patient randomization. Jon Young from Veeva emphasized that these advancements will help Vita Global Sciences achieve faster, more accurate trials.
Veeva Systems (NYSE: VEEV) announced that Hangzhou Tigermed Consulting has chosen Veeva Vault EDC as its foundational technology for electronic data capture (EDC). This adoption is expected to streamline complex data management processes, enabling faster study builds and mid-study amendments without downtime. Tigermed aims to enhance clinical trial management and data quality, benefiting both their clients and the broader industry. The collaboration with Veeva aligns with Tigermed's ongoing investment in new technology to maintain a competitive edge in clinical research. Veeva Vault EDC is part of Veeva's Clinical Platform, widely used by top biopharmaceutical companies and contract research organizations (CROs).
Veeva Systems (NYSE: VEEV) has announced their participation in two upcoming investor conferences. Paul Shawah, EVP of Commercial Strategy, will present at the William Blair 44th Annual Growth Stock Conference in Chicago, IL, on June 5, 2024, at 2:00 p.m. Central Time. He will also present at the Baird 2024 Global Consumer, Technology & Services Conference in New York, NY, on June 6, 2024, at 9:40 a.m. Eastern Time. Both presentations will be webcast live and archived for later viewing on Veeva's investor relations website.
Veeva Systems (NYSE: VEEV) announced its fiscal 2025 first quarter results with total revenues reaching $650.3 million, up 24% year-over-year. Subscription services revenue increased by 29% to $534 million. The company reported a significant rise in operating income, which grew by 152% to $155.2 million, and non-GAAP operating income increased by 66% to $260.9 million. Net income saw an increase of 23% to $161.7 million, with non-GAAP net income rising by 67% to $247 million. Earnings per share (EPS) also grew, with fully diluted net income per share at $0.98 and non-GAAP fully diluted net income per share at $1.50. Veeva highlighted key wins with top biopharmas, progress in CRM and Data Cloud solutions, and provided positive guidance for the upcoming quarters.
Veeva Systems (NYSE: VEEV) unveiled findings from its Veeva Pulse Field Trends Report, highlighting a significant drop in healthcare professional (HCP) access, now at 45% compared to 60% eighteen months ago. The report underscores the effectiveness of a connected engagement model, where sales, marketing, and medical teams coordinate efforts to build more relevant and trusted HCP relationships. This approach helps biopharma companies overcome access barriers, increasing HCP engagement through digital and in-person touchpoints. The findings indicate that HCPs are more selective, often engaging with only three or fewer companies, and that specialties such as internal medicine, oncology, psychiatry, and urology have stricter access limitations. Despite these challenges, coordinated engagement has proven beneficial in extending conversations and improving treatment adoption.
Veeva Systems (NYSE: VEEV) announced that its Veeva MedTech platform has been named 'Best Overall MedTech Software' for the second consecutive year in the MedTech Breakthrough Awards. The award recognizes Veeva MedTech's innovation and excellence in helping medical device and diagnostic companies streamline processes through its unified cloud platform. Veeva MedTech's solutions, including Veeva Vault Clinical, RIM, Quality, Commercial, and Medical, offer comprehensive lifecycle management. Veeva partners with over 125 companies to enhance efficiency, speed, and compliance. This marks Veeva MedTech's third recognition by MedTech Breakthrough, following a win for 'Best Clinical Efficiency Solution' in 2022.
FAQ
What is the current stock price of Veeva Systems (VEEV)?
What is the market cap of Veeva Systems (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
